




The relative strengths and weaknesses of Kura Oncology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 142% points. The greatest weakness of Kura Oncology Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 401%, being 125% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	522,289
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,455
Liabilities, Non-Current	4,987
Other Assets	9,089
Other Compr. Net Income	-1,835
Other Expenses	0
Other Liabilities	0
Other Net Income	792
Other Revenues	0
Property and Equipment	2,673
Research and Development	84,721
Selling, General and Administrative Expense	46,537

Output Variable	Value in 1000 USD
Assets	534,051
Liabilities	27,442
Expenses	131,258
Revenues	0
Stockholders Equity	506,609
Net Income	-130,466
Comprehensive Net Income	-131,384
BaseVar	347,689
ECR before LimitedLiability	347%
Economic Capital Ratio	401%